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Introduction 
 
 
The increasing prevalence of overweight and obesity among women of 
childbearing age, is a  growing public health problem in the world
.(1)
  The 
nutritional status represents one of the most important factor that determines 
individual wellbeing, in particolar maternal- fetal health, during and after 
pregnancy. 
(2)
 Obese women compared to normal-weight have a higher risk 
of having reduced sensitivity to insulin. The combination of obesity and 
reduced insulin sensitivity, increases the long-term risk of developing the 
metabolic syndrome. The number of pre-obese women (25> BMI <30) and 
obese (BMI> 30) who become pregnant is definitely on the rise 
(3)
 . The state 
of nutrition is one of the most important determinant  the welfare of the 
individual,  especially of the maternal-fetal development; often even the 
flexibility of the metabolic response of the pregnant woman is able to correct 
for the imbalance and nutritional pregravid / or metabolic alterations induced 
by lifestyle; therefore, negative events can be correlated with being 
overweight.. For metabolic disorders evolved during a normal pregnancy, 
particularly showing a 60% reduction in insulin sensitivity, these women 
have a higher risk of metabolic disregulation and complications and adverse 
fetal outcomes, including preeclampsia, gestational diabetes, increased 
incidence of cesarean section, macrosomia and fetal death 
(4)
. The metabolic 
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syndrome is a combination of cardiometabolic risk determinants such as 
obesity, insulin resistance, glucose intolerance, dyslipidemia, non-alcoholic 
fatty liver, hypertension. Pregnancy in these women may be seen as a 
metabolic stress test for the future risk of metabolic syndrome. 
The prevalence of the metabolic syndrome is increasing worldwide as a 
result of obesity, with a significant impact on the incidence of cardiovascular 
disease and type 2 diabetes. 
(5)
 
 
Definition and epidemiology of obesity 
 
 
Obesity is a chronic multifactorial etiology characterized by excessive body 
weight for accumulation of adipose tissue. Recently, the WHO (World 
Health Organization) has set new criteria for classifying obesity based on 
BMI (Body Mass Index), obtainable from the weight / height squared ( kg 
/m2) : as the upper limit of normal was set a BMI value of 24.9 Kg/m2 while 
were defined obesity I, II and III, respectively, including the values of BMI 
between 25 and 29.9Kg/m2, between 30 and 39.9Kg/m2 and more than 
40Kg/m2.  
Being overweight or obese, increases the risk of morbidity and mortality 
caused by the onset of other diseases such as diabetes mellitus type 2, 
hypertension, heart disease and several forms of cancer 
(6)
. Obesity is the 
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most common nutritional disorder in the western world and its prevalence is 
on the increase even in countries in development
(7)
. Today there is a lot of 
concern about their body weight, in fact recent estimates indicate a 
prevalence of obesity in 15% of the European adult population, and in many 
regions is increasing. The most worrying data come from the U.S., where 
about half the population is overweight and about one-fourth net is obese. 
More specifically, recent data indicate that  22.5% of the population is obese 
versus 14.5% in 1980 
(7-8)
. Experts have called the explosion a veritable 
epidemic of obesity that has touched all demographic groups even children. 
In Italy, the estimates derived from the first two quarters of the ISTAT 
survey (1999/2000), whereas the WHO classification 
(9)
 in the four classes: 
underweight (BMI <18.5), normal weight (BMI between 18.5 -24.99), 
overweight (BMI 25 to 29.99) and obesity (BMI ≥ 30) (4), indicates that the 
majority of adults, 53.8% is in a state of normal weight, well an adult three 
turns out to be overweight (33.4%), 9.1% is obese, and the remaining 3.6% 
are underweight. (Tab.1) 
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BMI < 18.5 Kg/m2 Underweight 
BMI  18.5-24.9 Kg/m2 Normal 
BMI 25-29.9 Kg/m2 Overweight 
BMI >30 Kg/m2 Obese 
Tab 1. BMI score (WHO Classification). 
 
 
Pathogenesis of obesity 
 
An understanding of the causes and ways through which obesity is spreading 
so rapidly, is the subject of increasing attention from reserchers and experts, 
who agree in emphasizing the existence of a strong interrelationship between 
genetic , physiological, metabolic, behavioral, and psychosocial factors. 
Obesity is therefore the resultant of the variable combination of two 
elements: genetic susceptibility, ie of a genetic predisposition of the 
individual to become obese, and the presence of environmental factors (eg: 
easy access to high-energy foods, sedentary lifestyle).  
It is believed that the genetic component impinges for the 30 - 40% and the 
environmental / behavioral for the remaining 60-70% (10) 
 In the years , research conducted to improve the understanding of the 
development of obesity have led ever more to consider genetic factors as key 
players in the onset of human Obesity stimulating numerous studies to 
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evaluate the role of family factors. There are many studies emphasize  the 
high incidence of Obesity in children of obese parents: the numbers ranging 
from an incidence of around 40% if one parent is obese, over 70% if they are 
both. 
 However, it’s important be taken into account of environmental factors. It is 
recognized that some genotypes thrive in a specific environment and less in 
another; and conversely a certain environment will exalt some 
manifestations and it will inhibit other. 
(11)
 
Obesity is widely recognized as a chronic disease, which can have a 
significant impact on collective health. It is the main factor responsible for 
non-insulin dependent diabetes mellitus and coronary heart disease, but also 
increases the risk of  biliary disorders and certain cancers, and play  a role in 
musculoskeletal disorders and  in the respiratory diseases. Despite these 
evidence, the prevalence of obesity is growing, so that experts believe that 
obesity should be considered one of the greatest public health issue of our 
time.
(12)
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Metabolic Syndrome 
Metabolic syndrome also known as metabolic syndrome X, 
cardiometabolic syndrome, syndrome X, insulin resistance syndrome, 
Reaven's syndrome  is a disorder of energy utilization and storage, 
diagnosed by a co-occurrence of three out of five of the following medical 
conditions: abdominal (central) obesity, elevated blood pressure, elevated 
fasting plasma glucose, high serum triglycerides, and low high-density 
cholesterol (HDL) levels. Metabolic syndrome increases the risk of 
developing cardiovascular disease, particularly heart failure, and diabetes. 
Some studies have shown the prevalence in the USA to be an estimated 34% 
of the adult population, and the prevalence increases with age. 
Therefore, the syndrome has been renamed "plurimetabolic", including the 
association of insulin resistance, central obesity, type 2 diabetes mellitus, 
dyslipidemia and hypertension. Many epidemiological studies have 
evaluated the various aspects of the metabolic syndrome evaluating them 
individually, and only some of them have considered a "cluster" of risk 
factors. 
(13)
 
The metabolic syndrome, according to the definition proposed by the World 
Health Organization (WHO) and then modified in part by the European 
Group for the Study of Insulin Resistance (EGIR), is characterized by the 
following risk factors:  
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Insulin- resistance defined by the presence of hyperinsulinemia and by high 
levels of glucose in fasting  blood of at least 110 mg / dL and by the 
presence of at least two of the following criteria: 
abdominal obesity defined on the basis of two definitions : 
- according to the original definition of the WHO, as waist-hip ratio> 0.90 or 
BMI≥ 30kg/m2; 
- according to EGIR, as waist-hip ratio ≥ 94cm;  
dyslipidemia with serum triglycerides ≥ 150 mg / dL (≥ 1.70 mmol / L) or 
HDL cholesterol <35 mg / dL (<0.90 mmol / L) 
 hypertension that is based on two definitions: 
- according to the original definition of the WHO, with pressure values ≥  
160/90mmHg; 
- according to the modification by EGIR,  with pressure values of 
140/90mmHg; 
The clinical significance of the metabolic syndrome becomes particularly 
important when you consider that the set of metabolic disorders typical of 
this syndrome seems to play an essential role in the genesis of cardiovascular 
disease and diabetes mellitus type 2. In  patients with metabolic syndrome 
there is a high mortality from ischemic heart disease. 
(14)
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Obesity and pregnancy 
Obesity in pregnancy (pregravid body mass index ≥ 30) has been linked to 
several adverse pregnancy outcomes, including spontaneous abortion, 
preeclampsia, gestational diabetes, fetal macrosomia, cesarean delivery, and 
many complications post–cesarean section. Intrapartum and postpartum 
management of obese gravidas requires multidisciplinary consultations 
between obstetricians, anesthesiologists, nurses, and pediatricians in order to 
improve the pregnancy outcomes of the mother and neonate. 
(15)
 
The assessment of BMI in the preconception period allows the identification 
of pregnants will present an additional risk related to changes in metabolic 
parameters.  The abnormalities of nutrition if not corrected have  the ability 
to compromise the maternal-fetal health short-and long-term. 
Maternal nutritional deficiencies are most commonly associated with 
preterm low, placental and neonatal low birth weight as confirmed by recent 
studies;
(16) 
controversial are those relating to the risk of fetal and neonatal 
death. 
A prominent study carried out between 89 and '96 has evaluated the 
association between pregravid BMI and obstetric outcome. In the  study 
carried out on a total sample of 24. 505 singleton pregnancies was not 
significantly increased the incidence of stillbirth and neonatal death  in 
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women with low BMI compared to obese women, who had twice the risk 
compared to the rest of the sample examined.  
(17)
 
It was also demonstrated that obesity and overweight is associated with an 
increased risk of gestational diabetes, pre-eclampsia, hypertension, 
eclampsia, macrosomia and fetal morbidity, preterm delivery, and cesarean 
section compared to normal weight pregnant women. 
(17-18)
 
Among the fetal complications appear to be increased in the obese 
population neural tube defects (NTDs) 
(19)
 and minor malformations such as 
cleft lip and palate, clubfoot, and cardiac defects.  
Still controversial results regarding the incidence of complicated deliveries 
from shoulder dystocia and brachial plexus injuries. 
Analyzing the most recent data in the literature is how many of these do not 
show an increased frequency of these complications in pregnant women with 
high BMI contrary to what proved to be older studies.  
This failure to increase should be in relation with the highest percentage of 
caesarean sections performed in pregnancies complicated; this percentage 
increases with increasing weight of the pregnant woman. 
However, there are studies which emphasize  the idea  that obstetric 
complications occur more frequently in infants born to mothers with obesity 
and / or diabetes; these conditions favoring the increase in fetal weight > 90 
° percentile. 
(20)
 In obese patients there are higher anesthetic complications 
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(difficult intubations, complicated and long procedures). Epidemiological 
studies have also found a direct correlation between high maternal weight ,  
the weight of the child at birth and in adulthood demonstrating how 
pregravidi inadequate nutritional status of the mother may be a pathogenic 
factor responsible for the onset of obesity in future generations. 
An appropriate weight gain during pregnancy can ensure the well-being of 
the mother and fetus, influencing the structure metabolic maternal-fetal unit.  
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Abstract 
Obesity pregnancy and maternal-fetal outcomes. 
Quaglia F. et al. 
 
Introduction: 
The prevalence of obesity in pregnant women is approximately 20-30%. 
This is an increasingly growing health problem. Obesity during pregnancy is 
considered a state high-risk because there is a correlation between pre-
gestational BMI and adverse maternal and fetal outcomes,as gestational 
hypertension, gestational diabetes, the failure of induction of labour, preterm 
birth, intrauterine fetal death, first caesarean section, fetal growth restriction 
and macrosomia. 
 
Material and Methods. 
The main objective of the study was to correlate pre-gestational weight, 
measured by the body mass index (BMI), and gestational weight gain with 
NICU admission and fetal or neonatal death. 
In our retrospective study, we included 35 singleton pregnancies of women 
with a BMI> 30 followed in our High-Risk pregnancy department between 
2008 and 2013.  
For each pregnant with single fetus were collected data about age, 
anthropometric measurements necessary for calculating the BMI, 
16 
 
information about obstetric anamnesis, complications and any medications 
taken during pregnancy. We collected also data on maternal diseases in 
particular diabetes, hypertension, preeclampsia. For the neonatal outcome 
were collected data on: sex, weight, Apgar scores at 1 and 5 minutes and 
admission at NICU. We compared  pregestational BMI and gestational 
weight gain in cases with NICU admission versus controls; we also 
compared pregestational BMI and gestational weight gain in women with 
fetal or neonatal death and controls. Statistical analysis was carried out using 
the Statistical Package for Social Sciences (SPSS) Statistics v. 19 (IBM Inc., 
Armonk, New York, USA). 
 
Results 
In our population 12 women had babies admitted at NICU and 4 women had 
fetal or neonatal death. No statistical difference was observed in mean 
pregestational BMI between women with or without NICU admission 
(37.45; SD 6.74 vs 40.17; SD 8.07; p=0.37) and in women with or without 
fetal or neonatal death (35.85; SD 4.16 vs 39.93; SD 8.02; p=0.33). A 
statistical difference was observed in mean gestational weight gain weight 
between women with or without NICU admission (14.87; SD 16.67 vs 6.02; 
SD 7.33; p<0.05) and in women with or without fetal or neonatal death 
(23.00; SD 17.58 vs 6.12; SD 7.93; p<0.05). 
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Conclusion 
Our results show that even if pregestational weight has been showed to be 
associated with adverse fetal and neonatal outcomes, gestational weight gain 
maybe is more important as risk factor for the developing of adverse 
outcomes in pregnancies complicated by obesity. Thus a strict medical 
control on maternal nutrition and weight gain should be done in pregnancies 
complicated by obesity. 
 
 
 Submission will be in process. 
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The role of epigenetic in obese pregnant women.   
In the past fifty years, the prevalence of obesity in the world has increased at 
an alarming rate . In addition, recent data indicate that 30% of American 
women of reproductive age are obese and 8% achieved a degree of severe 
obesity , it strives to clarify the harmful effects of obesity in pregnancy. 
(1)
 
Different critical periods during childhood appear to influence the 
subsequent development of obesity: the prenatal period, the stabilization of 
adiposity between 5 and 7 years old, and puberty. 
(2)
 
The prenatal period, ie from conception to birth is a period of rapid growth, 
replication and cell differentiation, and maturation of cellular and organ 
systems. 
 During pregnancy, the mother, placenta and fetus interact to modulate fetal 
growth. The fetal placenta ensures homeostasis playing a wide range of 
physiological functions. The alterations that modify one or more aspects of 
placental structure and function may have long-term repercussions on the 
health of the individual. 
(3)
 
For example, the placental weight and birth weight (correlated) may 
predispose to adult diseases such as obesity, type 2 diabetes and 
hypertension . In addition, changes in the structure placenta (placenta thicker 
change the barrier and increases the placental vascular resistance) are 
directly involved in the fetal programming of cardiovascular disease.
(3)
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The placenta may act as a sensor of nutrients, such as may change the 
availability of nutrients and hormones to the feto-placental tissues in relation 
to environmental conditions in order to maximize fetal growth, it also 
supports the pregnancy in order to ensure the delivery of a newborn able to 
live. 
(4)
 
 The intrauterine growth retardation induced in animal models in different 
ways (including hyper-and hypo-nutrition, isocaloric modification of the 
content of macro-and micro-nutrients in the diet, maternal stress, hypoxemia, 
glucocorticoid administration, and restriction of blood flow uterine) causes  
functional postnatal abnormalities . Finally, obesity has been demonstrated 
an intense inflammatory response in the placenta and that, by changing the 
environment in which the fetus develops, it could have consequences in the 
short-and long-term effects on his health.  
These observations suggest that adult diseases may originate in utero as a 
result of the development of intrauterine conditions that induce optimal 
permanent changes in the morphology and function of tissue, a process 
called "fetal programming or intrauterine". 
(4-6)
  
The fetal programming implies the plasticity of development, so as to allow 
the fetus to respond to environmental influences present or planned, with 
adaptive mechanisms (ie changing its metabolism and growth). The process 
by which an individual in development work permanent changes 
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advantageous for the future life, is known as "response presumed 
adaptation". Such fetal response may be inappropriate if the post-natal 
conditions are different from those expected, and this discrepancy can cause 
a disease in the adult. 
(7)
 Since the placenta is the active interface between 
the maternal and fetal blood, alterations in the levels of nutrients, cytokines, 
hormones, and reduced utero placental flow, must be transmitted through the 
placenta to the fetus in order to influence. 
The mechanism that binds an intrauterine environment unfavorable to the 
disease of the adult is still in the study, however, studies in animal models 
have shown that the epigenetic regulation (eg. DNA methylation) of fetal 
genes in metabolic pathways key is an important mechanism of fetal 
programming. 
(6)
 
In humans, have been also identified non-coding RNA imprinted genes, 
although their role has not yet been clarified is hypothesized to play an 
important role in some pathological conditions (eg, cancer, and Prader-Willi 
syndrome, a disease associated with the latter obesity). 
(8)
 
 In addition, altered expression of miRNAs (non-coding RNA) (compared to 
control placentas) was detected in human placentas of women with pre-
eclampsia, suggesting that the down-regulation of genes potential targets can 
contribute to this pathology. 
(9-10)
 In conclusion, there is evidence to show 
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that the epigenetic regulation of fetal genes could be an important 
mechanism that mediates the fetal programming of obesity. 
In view of the following findings, we therefore assessed in placentas and 
amniotic mesenchymal stromal cells (hAMSCs) isolated at birth from 
placentas of obese pregnant women, the presence of epigenetic mechanisms 
of gene regulation (DNA methylation, miRNAs) different from those 
observed pregnant women in non-obese and that may represent risk factors 
for obesity in the neonate.  
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miRNA-mediated gene regulation is different in placental tissues from 
obese and not obese pregnant women at delivery. 
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Epidemiological studies indicated that human adult diseases can be 
originated in uterus, as a result of changes in development during suboptimal 
intrauterine conditions that could alter the structure and function of the 
tissues. This process is called “fetal or intrauterine programming”. 
Experimental data indicate that the epigenetic regulation of fetal genes could 
be an important mechanism of the fetal programming of obesity. The aim of 
this study was to evaluate, in the placentas from obese and not obese 
pregnant women at delivery, the presence of a different miRNA-mediated 
regulation of the gene transcription. We recruited 5 not obese (BMI<30 
kg/m
2
) and 10 obese (BMI>30 kg/m
2
) pregnant women, to the term of the 
pregnancy. Total RNA was purified from sections of placentas collected 
during the Caesarean delivery. A panel of 365 human miRNAs was 
evaluated by the TaqMan Array Human MicroRNA Panel v1.0 (Applied 
Biosystems) system. By the TargetScan program we selected the target 
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genes of the miRNAs differently expressed in obese and not obese pregnant 
women, while the Gene Ontology program was used to identify the 
biological processes in which such genes were predicted to be involved. The 
results  evidenced that: 1) 78% of the miRNAs studied were expressed in the 
placental tissue; 2) 48% of the miRNAs showed a different expression in 
obese and not obese placentas; 3) gene targets of the overexpressed  
miRNAs belonged to the TGFβ- and insulin-signalling pathways. 
  
Introduction 
Obesity in pregnancy is increasing worldwide to almost epidemic 
proportions in developed countries and it is associated with increased risk of 
adverse outcomes for both mother and child.
1 
Maternal obesity and alteration 
in postnatal nutrition are associated in the offspring with increased risks for 
obesity, and for obese associated diseases such as hypertension and type 2 
diabetes.
2
 The process by which the structure and function of tissues could 
be altered permanently by insults acting during intrauterine development is 
called “intrauterine or fetal programming”.3 The in utero environment can 
substantially modify the fetal genome expression and exert stimulatory or 
inhibitory effects on fetal growth and adiposity.
4
 The mechanisms, whereby 
maternal obesity and nutrient excess in utero, in part increased risk for future 
metabolic disease, are poorly understood but likely include changes in fetal 
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nutrient supply in combination with genetic and epigenetic mechanisms.
4 
Epigenetics investigates mechanisms of inheritance which are not associated 
with changes in the gene sequence. The major epigenetic processes are DNA 
methylation, hystone modifications and microRNAs (miRNAs).
5-7
 MiRNAs 
are a class of endogenous non-coding RNA molecules, 18-25 nucleotides 
long that exert a tissue-specific regulation in a variety of biological and 
pathological processes such as adipocyte differentiation, insulin resistance, 
appetite regulation, diabetes and cancer.
8
 Altered miRNAs expression in 
human placenta has been involved in preeclampsia or small for gestational 
age (SGA) newborns.
9,10
 Further, the potential role of maternal serum 
miRNAs as marker for fetal congenital heart defects has also been 
described.
11
 It follows that the study of miRNA-regulated pathways during 
pregnancy both in normal weight and obese women could highlight 
patogenetic mechanisms underlying this metabolic disorder and address 
therapeutic approaches to prevent obesity insurgence in newborns. Our aim 
was to characterize the miRNA expression profile of amnion from obese and 
non-obese pregnant women at delivery in order to define a miRNA-signature 
associated with obesity and to evidentiate metabolic pathway potentially 
deregulated by this mechanisms. We focused on the amnion because 
alterations in this fetal membrane could have important consequences for the 
growth and intrauterine programming of the fetus. 
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Materials and Methods 
Patients 
Fifteen Caucasian  pregnant women were enrolled in this study. The women 
were divided into two groups based on body mass index (BMI) before 
pregnancy: non-obese pregnant women <25Kg/m
2
 (n=5) and obese pregnant 
women >30Kg/m
2
 (n=10). Clinical and anamnestic mother’s data were 
collected before the delivery. Cancer, viral infection and drug abuse were 
exclusion criteria. Maternal blood was obtained immediately before delivery 
and was centrifuged at 2500 rpm for 15 minutes, then the serum sample was 
stored at -80 °C until using. A cord blood sample was collected at delivery 
and within 1h from the collection cord plasma and mononuclear cells 
(MNC) were obtained by Ficoll density gradient centrifugation. Cord plasma 
and MNCs were immediately recovered and cryopreserved at -20°C and in 
liquid nitrogen, respectively. 
Human term placentas were collected from all pregnant women. The 
samples were obtained after caesarean section and were immediately 
processed. Firstly, the maternal decidua was removed, and then the amnion 
was manually separated from chorion and washed in phosphate-buffered 
saline (PBS, Sigma-Aldrich, St Louis, USA). Finally, the amnion was 
mechanically minced into small pieces and immediately cryopreserved in 
liquid nitrogen.
12
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The MNC isolated from cord blood and visceral and subcutaneous adipose 
tissues collected from all pregnant women were not used for this study.  
Newborns general characteristics, that are birth weight, length, head 
circumference, Apgar score (Appearance, Pulse, Grimace, Activity, 
Respiration) were registered immediately at birth. Each pregnant women 
provided written informed consent for herself and her newborn to the study 
and the research protocol was approved by the Ethics Committee of our 
Faculty of Medicine.  
Laboratory investigations 
Main biochemical parameters, leptin and adiponectin were measured 
respectively by routine laboratory methods and Luminex xMAP Technology 
on a BioRad Multiplex Suspension Array System (Bio-Rad, Hemel 
Hempstead, Herts), according to the manufacturer’s instructions both in 
mother’s serum and in cord plasma. 
RNA isolation 
Total RNA (including miRNAs) was purified from amnion using the 
mirVana
TM
 miRNA isolation kit (Ambion) and its concentration was 
evaluated by NanoDrop® ND-1000 UV-Vis spectrophotometer (NanoDrop 
Technologies, Wilmington, DE, USA). The RNA isolated from amnion of 
non-obese pregnant women was pooled to set up a control pool RNA. 
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MiRNA expression profile 
TaqMan low density arrays (TLDA), micro fluidic cards were used to detect 
and quantify mature miRNAs according to manufacturer’s instructions. Each 
TLDA Human MicroRNA Panel v1.0 card contained 365 preloaded human 
miRNA targets and two endogenous controls (small nuclear RNAs: RNU48 
and RNU44). TLDAs were prepared in two-steps. In the first step, 640 ng of 
total RNA were reverse transcribed in eight multiplex reverse transcriptase 
(RT) reaction pools using stem loop RT primers specific for mature miRNA 
species. Then, each of the resulting eight cDNA pools was diluted, mixed 
with TaqMan Universal PCR master mix, and loaded into one of the eight 
fill ports on the TLDA microfluidic card. The card was centrifuged for 2 min 
at 1200 rpm to distribute samples to the multiple wells of the fill ports and 
sealed to prevent well-to-well contamination.  
Finally, the cards were processed on an 7900 HT Real-Time PCR System 
(Applied Biosystems). The miRNA expression values were normalized to 
RNU48 (endogenous control), and relative expression values were obtained 
using the ΔΔCT method (Relative Quantification, RQ=2-ΔΔCT) with 
Sequence Detection System (SDS) v2.3 and RQ Manager 1.2 software 
(Applied Biosystems). To further normalize our miRNA data and to 
minimize interindividual variability, we considered differently expressed the 
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miRNAs whose mean RQ levels were <0.5 (down-expressed) or >2.0 (up-
expressed) in at least 7/10 obese pregnant women vs the control pool. 
 
Bioinformatic analysis 
Biological targets of miRNAs differently expressed in obese pregnant 
women vs the control pool were predicted using the TargetScan Release 6.2 
algorithm (http://www.targetscan.org). This algorithm assigns a “total 
context score” for each predicted target. Target genes with an “total context 
score” <-0.30 were further analyzed using the KEGG database 
(http://www.genome.ad.jp/kegg/) to identify the pathways involving the 
target genes of miRNAs. By this latter program we selected the biological 
pathways that contained at least two predicted genes to be miRNA-altered in 
obese samples with a statistically significant probability (P<0.001). 
 
Statistical analysis 
All variables were expressed as mean ± standard error of the mean (SEM). 
Student “t” test was used to compare group means and P values <0.05 were 
considered significant. Statistical analyses were carried out by using the 
PASW Statistics (Ver.18; SPSS Inc. Headquarters, Chicago, Ill).  
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Results  
Higher values of leptin (P-value=0.01) and L/A ratio (P-value =0.001) were 
measured in obese vs non-obese pregnant women. Instead, the adiponectin 
serum levels were lower, even if not at statistically significant level. The 
weight gain and the total cholesterol levels were significantly lower in obese 
than in non-obese pregnant women (P-value=0.008 and P-value 0.016). In 
addition, among parameters evaluated in newborns we found that only the 
cord plasma adiponectin was statistically different with lower levels in the 
newborns from obese mothers than those from non-obese mothers (P-
value=0.004).  
Alarge percentage of the tested miRNAs about 74% (271/365) was 
expressed in amnion, whereas 26% (94/365) was not. Most of the expressed 
miRNAs (90% 243/271) did not differ between obese women and controls 
and were not further investigated. Conversely. 4.8% of miRNAs (13/271) 
were higher (Fig 1a) and 4.4% (12/271)were lower (Fig.1b) in obese women 
than in controls.  
Interestingly, 7/271 miRNAs (miR-422b, miR-219, miR-575,miR-523, miR-
579, miR-618 and miR-659) were obesity-specific, being expressed only in 
amnion from obese women. 
Bioinformatics showed that miRNAs had a significant probability (P<0.01) 
of deregulating several genes and metabolic pathways (Figures 1c, d and 2). 
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The expression levels of several miRNAs were further validated by 
quantitative real-time polymerase chain reaction and, except for slight 
differences because of the two different methodologies, they were in close 
agreement with those obtained with TaqMan array  (mean RQ values in 
obese vs control: miR-422b¼6.4;miR-23b¼1.19; miR-338¼1.25; miR-
139¼0.68; miR-449b¼0.9). 
 
Discussion 
The present study is the first to evaluate the miRNAs profiling in human 
amnion of obese pregnant women. Previous reports revealed that altered 
miRNA expression profile in placenta may have important implications for 
several placental injuries such as preeclampsia, hypoxia, fetal growth 
restriction, preterm labor and choriocarcinoma.
9,10,13
 No data are yet 
available in literature regarding differential expression of miRNAs in 
placentas of obese women, so our aim has been to characterize the miRNA 
expression profile of amnion from obese and non-obese pregnant women at 
delivery. Furthermore, in our study population, we also evaluated some 
biochemical parameters and the leptin and adiponectin levels. In Table 1 are 
reported the clinical and biochemical characteristics of obese and non-obese 
women, and of their respective children.  
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In According to Gestational Weight Gain (GWG) guidelines US Institute of 
Medicine (IOM) published on 2009, we found an higher weight gain in non-
obese women than obese during pregnancy.
14
 In our obese group we found 
the increased leptin and decreased adiponectin levels, normally associated 
with elevated body mass index.
15
 Leptin is an adipokine mainly produced by 
adipose tissue, its major biological role is regulation of energy balance, 
regulating food intake, glucose uptake, insulin secretion and action. Leptin is 
also secreted by placenta and so its concentrations increases during 
pregnancy.
16
 In fact, an increase of four fold of leptin levels is measured in 
our non-obese pregnant women than non-obese women without pregnancy 
(these latter were previously analyzed in another our study). Instead, in our 
obese pregnant women we observed an increase of about seven fold than 
obese women without pregnancy (these latter were previously analyzed in 
another our study), probably due to additive effect of obesity and pregnancy. 
Our results are in agreement with previous studies, that showed a higher 
serum leptin concentrations in overweight pregnant women when compared 
to normal weight.
17
 As previously reported, it is possible that exposure to 
high or low concentrations of leptin, during critical periods of development 
of the neural network that regulates appetite may be have longer term 
consequences for this network and for the regulation of energy balance after 
birth.
18
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Adiponectin is another adipokine produced by adipose tissue that acts as an 
antidiabetic, anti-inflammatory and antiaterogenic hormone. Previous reports 
showed no differences in adiponectin levels between non pregnant and 
pregnant women, suggesting that the placenta might not be the primary 
source of circulating adiponectin in pregnant women and that adipocytes 
play a major role in adiponectin production.
19
 This finding supports our 
lower adiponectin levels observed in our obese than non-obese pregnant 
women. We also observed a significantly lower levels of adiponectin in cord 
plasma of newborns from obese than non-obese mothers, agreeing with a 
previous report in which the authors suggested that, due to lower circulating 
anti-inflammatory cytokines, fetuses from obese women may be less able to 
control the inflammatory process and affecting the optimal fetal 
development.
20
 Furthermore, we found that the obese pregnant women 
showed a lower levels of total cholesterol than non-obese women. These 
findings are previously reported by Varhatian A. et al. that observed a 
different lipid profile during pregnancy in obese than normal weight women. 
In particular, these authors found in the third-trimester of pregnancy lower 
total and LDL cholesterol levels in overweight or obese than normal-weight 
women, probably due to metabolic deregulation associated with maternal 
obesity that could affect the fetus predisposing it to metabolic diseases.
21
 
33 
 
It is now recognized that epigenetic modifications of the fetal genome 
contribute to disease development in adults (7).  Here, we show that 
miRNAs regulate gene expression in the amnion during obesity. In 
particular, we found that 25 miRNAs are differently expressed in obese with 
respect to control women, and have identified seven obesity-specific 
miRNAs. 
Our differently expressed placental miRNAs include miRNAs previously 
associated with endometriosis (miR-196b, let-7d and miR-107), 
preeclampsia (miR-181 and let-7d),(9-10)  cancer(miR-422b) or identified in 
sera from normal pregnancies (miR-23b,miR-372 and miR-519e). The 
predicted target genes of ourmiRNAs belong to pathways potentially 
important for placental development and/or functions. In fact, the 
neurotrophin pathway was regulated by three obesity-specific miRNAs 
(miR-422b, miR-659 and miR-575), six miRNAs upexpressed (miR-196b, 
miR-96, miR-338-3p, miR-372, miR-492 and miR-107) and four 
miRNAsdownexpressed (miR-591, miR-139, miR-624 and miR-554). 
The brain-derived neurotrophic factor was recently implicated in placental 
development and fetal growth in mice and its placental expression was 
increased in intrauterine growth restriction and decreased in maternal type 1 
diabetes. Obesity-specific miRNAs (miR-422b, miR-659 and miR-219) also 
downregulated the mammalian target of rapamycin (mTOR) and the insulin 
34 
 
signaling pathways. mTOR is highly expressed in syncytiotrophoblasts of 
the human placenta and exists as two complexes with distinct regulation and 
function based on its association with accessory proteins: raptor in Complex 
1 (mTORC1) and rictor in Complex 2 (mTORC2). (Fig.2) 
Some of these signaling pathways have been demonstrated to have important 
roles in placental development and functions. For example, TGF-
exerts several modulatory effects on trophoblast cells such as inhibition of 
proliferation and invasiveness, stimulation of differentiation.
22
 An altered 
expression of TGF- -eclamptic 
placentae.
23 
In humans, Wnts and GnRH signaling promote decidualization, endometrial 
function and trophoblast differentiation. Changes in Wnt signaling 
components were noticed in cancers of reproductive tissues, in 
endometriosis and in gestational diseases.
24, 25
 
Previous reports showed that also members of MAPKs family as ERK1/2, 
were expressed in the placenta, until the 12
th
 week of gestation, suggesting a 
predominant role during early pregnancy;
26
 furthermore, its activation was 
found elevated also during the early stages of adipogenesis.
27
 
Another study indicated that ERK was increased in placentas from patients 
with pre-eclampsia.
28
 Further investigations demonstrated an altered 
placental expression of insulin signaling components in insulin controlled 
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GDM (gestational diabetes mellitus) in comparison with normal pregnant 
controls in both obese and non-obese cohorts, changes were also detected in 
normal obese pregnant women than normal non-obese.
29
 Placental 
expression of several insulin signaling components were also reduced in 
pregnancies complicated by IUGR (intrauterine growth restriction).
30 
 
The cytoskeleton plays a crucial role in basic cellular processes, such as 
mitosis, growth, motility, aging, smooth muscle contraction, and apoptosis. 
The reorganization of the cytoskeleton is involved in decidualization,
31
 and 
so an altered regulation of actin cytoskeleton signaling was observed in 
preeclamptic placentae.
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Regulation of epithelial organization, structure, and subsequent function is 
modulated by two forms of junctional complexes, tight junctions (TJs) and 
adherens junctions. Amniotic TJs may be regulated by several factors in the 
amniotic fluid and they may be involved in normal or abnormal 
(oligohydramnios and polyhydramnios) volume changes of the amniotic 
fluid.
33
 Has been found a decreased expression of some tight junction 
proteins in preclamptic human term placentae.
34
 
The adherens junction has a considerable effect on endothelial integrity and 
has been implicated in the stability of junctions, angiogenesis and 
intracellular signaling, therefore they are important in understanding how the 
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placental endothelial barrier is regulated during pregnancy in health and in 
disease.
35
 
The intracellular cytoskeleton is connected to the extracellular matrix by the 
focal adhesion complexes that transmit force at cell adhesion site and serve 
as signaling centers from which numerous intracellular pathways can 
regulate cell growth, proliferation, survival, gene expression, development, 
tissue repair, migration, and invasion.
36,37 
Previous studies in rodent 
myometrium have demonstrated that focal adhesion signaling is activated at 
late pregnancy.
36
 
Recent evidence indicated that in the development of the feto-placental unit 
may also be implicated the neurotrophins. In mice, in fact, it has been shown 
that the brain-derived neurotrophic factor (BDNF) exerts autocrine/paracrine 
roles in the placenta, potentiates both placental development and fetal 
growth from mid gestation to late gestational stages. The placental 
BDNF/TrkB signaling system is modulated in pregnancies with fetal growth 
perturbations, in fact, in IUGR the placental BDNF expression was increased 
while its expression was decreased in maternal type 1 diabetes.
38
 
An altered expression of some proteins involved in selective proteolysis via 
the ubiquitin-proteasome system was revealed in placenta from IUGR and 
preeclamptic pregnant women.
39
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Furthermore, among dysregulated pathways in our patients, we also found 
some associated with cardiovascular diseases. An increased susceptibility to 
myocardial injury in offspring from obese dams has been previously 
described.
40
 
More recent studies suggested that obesity also results in cognitive 
impairment and the mechanisms involved include hyperglycemia, 
hyperinsulinemia and vascular damage to the central nervous system.
 41
 In 
particular, leptin regulates hippocampal plasticity by converting short term 
potentiation in long term potentiation, a functional enhancement that may 
contribute to leptin’s ability to improve hippocampal-dependent behavioral 
performance.
42
 Hypertriglyceridemia, observed in obesity, can impair the 
transport of leptin across the blood-brain barrier causing the cognitive 
disturbances in diet-induced obesity.
41
 
In conclusion, the results of the present study reveal, for the first time, an 
altered miRNA expression in human amnion from obese women. This 
suggests that the differently expressed miRNAs could deregulate the 
pathways above mentioned and have therefore potential effects on fetal 
development, increasing the risks of metabolic diseases in adulthood. 
Further studies are needed to corroborate our hypotheses and to clarify the 
molecular mechanisms involved in fetal programming of obesity. It would 
be interesting to monitor the children measuring anthropometrics and 
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biochemical parameters, to evidence risk factors predisposing to obesity in 
children from obese mothers. 
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MATERNAL OBESITY AND PREGNANCY COMPLICATION. 
 
Obesity was recognised as a risk factor in pregnancy more than 50years ago. 
(1) 
 
Since then, numerous retrospective, prospective and case-control studies 
have demonstrated the association between maternal obesity and various 
pregnancy complications that may occur in the preconception period, 
gestational and postnatal. 
 
Hypertensive disorders. Pre-eclampsia 
The hypertensive disorders are undoubtedly among the most frequently 
observed complications in obese women. Hypertension may be present 
before conception, or arise during the early periods of pregnancy (gestational 
hypertension), with or without evidence of pre-eclampsia. 
Pre-eclampsia occurs in 5-7% of healthy nulliparous women and is the 
second leading cause of maternal death in the U.S. and remains the most 
common cause of fetal death. 
(2)
  
Obesity, insulin resistance and hypertriglyceridemia cofactors are important 
for the development of endothelial dysfunction, which plays a central role in 
the pathogenesis of pre-eclampsia. Endothelial dysfunction reduces the 
secretion of prostacyclin and increases the production of peroxidase that 
results in vasoconstriction and platelet aggregation. 
(3)
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Large studies have shown that obese women have a two or three times 
greater probability of developing pre-eclampsia compared to normal weight. 
(4-5)  
A systematic  review of 13 studies by O'Brien et al. that included more 
than a million women, have shown that the risk of pre-eclampsia increases 
with increasing BMI. 
(4)
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Metabolic syndrome in patients and hematological diseases. 
 
 
The term metabolic syndrome (MS) defines a clustering of cardiovascular 
risk factors, formerly known as syndrome X. There is some debate about the 
diagnostic criteria; but the most widely accepted framework is that defined 
by the National Cholesterol Education Program Adult Treatment Panel III, 
which requires the simultaneous occurrence of at least three of abdominal 
obesity, arterial hypertension, hyperglycemia, hypertrigliceridemia and low 
high-density lipoprotein cholesterol (HDL-C). The prevalence of MS 
increases with age and varies depending on genetic factors. An abnormally 
high prevalence has been observed in patients with heterogeneous 
conditions, such as solid organ transplant recipients, AIDS patients and 
long-term cancer survivors
(1-2)
.  
As some of the pathogenetic factors possibly involved include cyclosporine 
A, corticosteroids and cancer chemoradiotherapy, it is possible that MS may 
also be a complication in hematological patients. Some of the characteristics 
of MS have been reported with a certain frequency in thalassemia patients, 
and are mainly attributed to iron overload. Impaired hemostasis is a feature 
of MS rather than a factor predisposing to its development. In 
oncohematology, an abnormally high  
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prevalence of MS features has been observed in survivors of pediatric acute 
lymphoblastic leukemia.  
In addition to corticosteroid- and cancer therapy-related hypogonadism, 
hypothyroidism and defective growth hormone incretion are other factors 
related to the development of MS. Moreover, the highest frequency of MS is 
observed in hematopoietic stem cell transplantation (HSCT) recipients. 
Pediatric patients and allogeneic HSCT recipients have been the subject of 
foremost investigations; but adult patients and autologous HSCT recipients 
have also been studied more recently. A wide range of factors may 
contribute to the development of MS in HSCT recipients. Unfortunately, the 
real entity of the problem is far from clear because of the retrospective 
design of the studies, the limited size of their populations and their 
heterogeneous selection criteria, thus making it difficult to determine 
whether MS is a transient and possibly reversible phenomenon or a true late 
effect of the procedure. 
Haemophilic  disorders. 
Hemophilia is characterized by spontaneous and provoked mucocutaneous, 
joint, muscle, gastrointestinal, and central nervous system bleeding, leading 
to major morbidity and even mortality if left untreated or undertreated. With 
the pioneering of safe plasma-derived and recombinant coagulation factor 
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and the initiation of prophylactic infusions of clotting factor, people with 
hemophilia are now living longer with fewer bleeding and infectious 
complications. As their life expectancy and lifestyles closer match those of 
their healthy peers, so does their risk for common public health issues, 
including overweight, obesity, and the ensuing complications. 
Obesity is a major contributing factor to the global burden of chronic disease 
and disability. According to the WHO, obesity rates have increased at least 
threefold since 1980 in parts of North America, the United Kingdom, 
Eastern Europe, the Middle East, the Pacific Islands, Australia, and China
.(3-
4)
  
Thromoembolic disorders 
Pregnancy is a hypercoagulable state and obesity increases the risk of 
thrombosis by promoting venous stasis, increasing blood viscosity and 
promoting activation of the coaugulation cascade. The greatest risk is at 
term, and expecially in association with cesarean delivery
(5)
. 
In a retrospective study of 683obese women and 660 normal weight women 
the  incidence of thromboembolism disease was 2.3 % in the obese group 
and 0.6% in the normal group
(6)
. 
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Thromboembolism is the leading cause of maternal death in pregnancy and 
is likely to increase in incidence as a consenquences of higher rates of 
maternal obesity in developed nations. 
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HAIRY CELL LEUKEMIA DURING PREGNANCY AND 
TREATMENT WITH INTERFERON-ALPHA: A CASE REPORT 
AND LITERATURE REVIEW  
Quaglia F., et al 
 
CLINICAL PRACTICE POINTS 
Hairy cell leukemia (HCL) is a chronic lymphoid leukemia recognized as a 
clonal B-cell malignancy. It was first described by Bouroncle et al. in 1985 
as leukaemic reticuloendotheliosis
1
and it was renamed HCL by Schrekand 
Donnelly because it is characterized by the presence of abnormal cells with  
hairlike cytoplasmatic projections on the surface.
2
 It is a rare form of 
leukemia, with an incidence rate less then 1/100000 cases per year. It affects 
mainly the male gender (male/female ratio 4:1) with a median age at 
diagnosis of 55-56 years and a Caucasian preponderance.
3
 
 
INTRODUCTION 
HCL  is extremely rare in pregnancy. Only few cases were reported in 
literature and they were summarized in Table1.  
Treatment options include purine analogues (cladribine), INF-α, 
splenectomy, or monoclonal antibodies (rituximab). 
Cladribine is often use as first line therapy , with complete remission rate of 
76-80%.
456
. However, it is not indicated in pregnancy because of its 
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teratogenic effects  and because it improves the risk of perinatal mortality.
7
 
Rituximab is a monoclonal antibody, producing an overall response rate of 
64% in HCL; it acts synergistically with cladribine.
8
 
We found a single case reporting the use of rituximad and cladribine in a 
pregnant woman with HCL, without complications for both the  mother and 
the fetus; in this case, the decision was guided by the advanced gestational 
age and the need for a rapid improvement of platelet count. 
9
 
An other therapeutic option is splenectomy, that permits an increase in blood 
cell count. Four cases of splenectomy in pregnant women developing HCL 
were described in literature (10-13) 
However splenectomy does not produce a remission of the pathology; 
moreover, there are potential risks of maternal hemorrhage and 
infections(REF). It is a real possibility only in the early gestation when the 
risks are lower. 
INF-α has a documented response rate of 75%-90% (14-15). INF-α is a 
pleyotropic cytokine with immunomodulatory properties. Even if it has been 
considered dangerous for a long time, it does not inhibit DNA synthesis and 
is not mutagenic in vitro or teratogenic in animal studies; moreover, previous 
studies showed that it does not reduce fertility (16-19). Negative effects are 
registered in the monkey only for doses higher than those used in pregnancy
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17.20 
Moreover, it was demonstrated that placenta  produces INF and INF-like 
molecules (throphoblast INF) 
(21)
. 
We have already reported four cases of successful pregnancies in women 
affected by essential thrombocythemia treated with INF-α. (22). Moreover, 
three previous cases of pregnant women with HCL showed good tolerance, 
uncomplicated pregnancy and delivery, and normal child development after 
delivery 
(23-24)
. Many adverse side effects are reported as a consequence of 
INF-α therapy, such as depression, fatigue and flu-like syntoms;9 9by the 
way, no adverse effects were recorded in our case and in cases decrypted 
before.  
DISCUSSION 
We report a case of successful pregnancy in a 30 years-old woman affected 
by HCL, treated by alfa-interferon. A 30 years-old pregnant woman, gravida 
I at 8 weeks of gestation, was referred to The High Risk Pregnancies Unit of 
the Department of Obstetrics & Gynecology (University of Naples “Federico 
II”) for a progressive pancytopenia.   On her initial blood count, white cell 
count was 3540/mm^3, platet 50.000/mm^3, hemoglobin  8.7 gr/dl, and 
neutrophil count was 45% with the presence of cells with cytoplasmic 
protusions.Immunophenotyping of B lymphocytes of peripheral blood and 
bone marrow aspirate showed a population of CD19+, CD103+, CD11c++, 
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CD25+ B cells (1,5%) compatible with a diagnosis of Hairy Cell Leukemia. 
(Figure1)  Therefore, our management was based on blood transfusion 
(when hemoglobin was less then 8 gr/dl) and prednisone 25 mg/die during 
the whole first trimester. The woman required five  blood-transfusions. At 
12 weeks of gestation, the possibility of a therapy with interpheron-alpha 
was discussed. A therapy with INF-α (Intron-A 3 M.U.I. three times per 
week) and prednisone 10 mg/die has been performing until delivery. After 
one month, a progressive increase of hematological parameters was observed 
and the patient did not receive other blood transfusions. INF-α was well 
tolerated. At 34 weeks of gestation, she was admitted to the hospital because 
of threatened preterm labor. Liggins’ prophylaxis and tocolytic therapy were 
performed. A female baby was delivery at 36 weeks of gestation with a 
birthweight of 2850 grams and Apgar score 9 and 10 at 1 and 5 minutes, 
respectively.Placental size was normal and there was not any infiltration of 
hairy cells.There was no complication during vaginal delivery.  Woman 
could perform breastfeeding because of the low interferon concentration in 
breast milk.  
She was discharged after nine days. Two years after, the patient underwent a 
teraphy with Cladribine, because of the reaapearance of splenomegaly and 
pancytopenia. Actually she is in clinical remission.  She is currently being 
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followed in the hematologic clinic. Her child had a normal growth and 
neurodevelopment at two years-old.  
 
CONCLUSION 
Even if nowadays HCL is a rare event during pregnancy, its management 
could become a consistent  problem because of the trend toward delaying 
pregnancy until later life.  
Unfortunately malignancies during pregnancies represents a difficult 
problem because of the teratogenic potential of most antineoplastic agents. 
Even if INF-α is actually considered the second line therapy for HCL, 
because of the slow onset of action and the risk for adverse side effects
ix
, we 
think that it is a valid terapheutic option in pregnant women affected by 
HCL because of the lower risks for both the mother an the fetus; other 
therapeutic options should be considered only when INF-α fails. 
 
 
 
 
 
    Fig.1 
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Table 1 
Reference Age Gestational age 
(GA) at 
diagnosis 
Type of 
therapy 
GA at 
delivery 
Obstetrical 
complications 
Type of 
delivery 
Birthweight 5 min 
APGA
R score 
Breastfeeding 
Stiles et al, 
1998 
   38 ws  Caesarean 
section 
2875 gr 9  
Kopec et 
al, 2005 
36 14ws INF-α 39 ws none Caesarean 
section 
3460 gr 10 no 
Baer et al, 
1992 (Pz 
3) 
32 14 ws INF-α Full term 
(non 
specificat
e le 
settimane) 
None TC Not specified Not 
specifie
d 
Not specified 
Baer et al 
1992 (Pz 
4) 
37 22 ws INF-α 34 ws None  Not specified  1584 gr Not 
specifie
d 
Not specified 
Williams 
et al, 1987 
34 7 ws None 37 ws None Caesarean 
section 
Not specified Not 
specifie
d 
Not specified 
Patsner et 
al, 1994 
36 Diagnosis 
before 
pregnancy 
 Evacuatio
n of 
pregnancy 
     
 
 
Submission will be in process 
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SYSTEMIC LUPUS ERYTHEMATHOSUS-ASSOCIATED 
THROMBOCYTOPENIA IN PREGNANCY: IS SPLENECTOMY 
NECESSARY AT THE TIME OF DELIVERY? 
F.Quaglia, et al. 
 
Abstract 
 
Background: Systemic Lupus Erythematosus (SLE) associated 
thrombocytopenia in pregnancy is a rare condition associated with potential 
harm to the mother, the fetus and/or newborn, if the thrombocytopenia is 
severe (< 50,000/mm
3
). Controversy persists regarding the role and the 
timing of splenectomy in patients with SLE-associated refractory immune 
thrombocytopenia in pregnancy. This report describes the use of 
splenectomy at the time of the Cesarean Section (CS) in a patient with 
refractory SLE-associated thrombocytopenia. 
Case: A 19-year-old gravida 2, para 1, woman with SLE- associated 
thrombocytopenia diagnosed at age 16, developed a platelet count of 10,000/ 
mm
3 
at the 18
th
 week of gestation. She had been asymptomatic until that 
point, except for a previous spontaneous abortion at the 8
th
 week of gestation 
in 2008  During this admission she was treated initially with 
methylprednisolone and enoxaparin but following an episode of epistaxis 
she received intravenous immunoglobulins (IVIG). She was discharged 
home with a platelet count of 52,000/ mm
3
. She was readmitted on the 34
th
 
week’s gestation with a platelet count of 15,000/mm3 unresponsive to 
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steroids and IVIG; she underwent a CS and an open splenectomy. Following 
surgery, she continued to receive maintenance dose steroids. She had a 
partial response to the splenectomy (platelet count on discharge 
63,000/mm
3
).   
CONCLUSION: Splenectomy at the time of the CS is a safe therapeutic 
option for women with SLE-associated refractory thrombocytopenia during 
pregnancy. 
 
INTRODUCTION 
Thrombocytopenia, defined as a platelet count less than 150,000/mm
3
, is 
encountered in 7% to 8% of normal pregnancies 
[1]
. This form of 
thrombocytopenia, defined gestational thrombocytopenia, is benign because 
it is not associated with increased bleeding tendency in the mother or with 
thrombocytopenia in the newborn. Typically, no therapy is required and 
normal vaginal delivery is the norm 
[2]
. However, the acute or chronic 
autoimmune thrombocytopenias of pregnancy, among these the SLE-
associated thrombocytopenia, may have a significant impact on the mother 
and/or the fetus/newborn 
[3, 4].
 Therefore, the rheumatologist and obstetrician 
treating such patients are confronted with complex therapeutic decisions, 
including the choice of medications 
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during the pregnancy, the timing and route of the delivery, the possibility of 
bleeding in the newborn from thrombocytopenia, and in those cases of 
thrombocytopenia refractory to medical treatment whether splenectomy 
should be undertaken to correct the immune-mediated thrombocytopenia in 
the pregnant woman.  In the following case report, we describe our approach 
to a young pregnant patient with SLE-associated thrombocytopenia 
refractory to medical treatment, which included splenectomy at the time of 
the CS, and we outline a potential decision tree based on the pertinent review 
of the available literature. 
 
CASE REPORT 
The patient is a 19-year-old woman, gravida 2, para 0, first diagnosed with 
SLE in 2006 at age 16 when she had developed thrombocytopenia. At the 
time of the diagnosis of SLE, she had been treated with bolus Intravenous 
(IV) methylprednisolone with a complete response (platelet count > 
150,000/mm
3
). She was treated subsequently with 6mg/day of 
methylprednisolone for one year at which time her platelet count had 
normalized. She remained asymptomatic with a normal platelet count, and in 
early 2008 she became pregnant but suffered a spontaneous abortion at the 
8
th
 week of gestation.  Following this event she remained asymptomatic. In 
November 2008, she became pregnant again. At this time, she underwent an 
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extensive hematologic and immunologic work up that showed normal 
thyroid and liver function tests, positive antinuclear antibodies (ANA), Anti-
Extractable nuclear antigen (ENA) antibodies, normal C4  with decreased C3, 
increased anticardiolipin (IgM) antibodies, elevated anti-β-glycoprotein, and 
a platelet count of 204,000/mm
3
. Vaginal and rectal swabs were negative for 
Streptococcus Agalactiae. She was given hydroxychloroquine, aspirin, and 
enoxoparin  subcutaneously 40 mg/day. Her platelet count remained 
relatively stable ranging between 80,000 and 100,000/mm
3
 until the 18
th
 
week of gestation when her blood work revealed a platelet count of 
11,000/mm
3
. At this time (2/13/2009), she was admitted to out department 
for further diagnostic work up and for appropriate treatment. Her laboratory 
work-up showed elevated ACA, ANA with decreased C3 level, normal PT, 
PTT, fibrinogen level (270mg/dl), and ATIII levels (95%). Heparin-induced 
thrombocytopenia was excluded by assaying anti heparin/PF4-antibodies 
titer. Her hemoglobin and hematocrit were 10.5 g/dl and 33%, respectively. 
She had anti-Ro/SSA and anti-La/SSB antibodies. Her rheumatoid factor 
was 23 IU/ml (upper limit of normal 15.9)(Tab 1). On 2/15/2009 her platelet 
count decreased to 9,000/mm
3
; at this time, she experienced epistaxis. She 
was treated with eight units of platelet concentrates and the 
methylprednisolone was increased from 16 mg to 24mg/day. In addition, she 
received intravenous IgG 400mg/day for five days. Her platelet count rose to 
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52,000/mm
3
 by March 8, 2009 when she was discharged home on 
methylprednisolone 6 mg/day, hydroxychloroquine, and aspirin. Her interval 
follow up examinations confirmed a satisfactory progression of her 
pregnancy with decreased platelet counts ranging between 20,000 and 
25,000/mm
3
 without any bleeding event. (Fig 1). On her 34
th
 week of 
gestation (May 20, 2009), she was admitted to our department with a 
treatment plan that included another course of IVIG with pulsed steroids in 
preparation for an elective CS. However, she failed to respond to the 
treatment (Fig 2). Based on her failure to respond to the IVIG therapy, the 
hematology consultant suggested that she should undergo splenectomy at the 
time of the CS. On 6/3/2009, her platelet count just before the CS was 
15,000/mm
3. 
She received eight units of platelets before a midline 
laparotomy through which a transverse segmental CS was done followed 
immediately by the splenectomy. The intraoperative and postoperative 
course was uneventful. Her postoperative platelet count rose to a nadir of 
63,000/mm
3
 on 6/10/2009 when she was discharged home. The treatment 
plan at this time included the use of Rituximab. A healthy newborn with a 
normal platelet count was delivered via CS.   
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Discussion   
This case report provides the opportunity to review several issues associated 
with the decision-making process concerning the management of SLE 
patients who develop thrombocytopenia during the pregnancy. 
 
Systemic Lupus Erythematosus in Pregnancy: fertility rate in SLE 
patients has been reported to be similar to that of the normal population 
[3]
. 
Earlier reports recommended that SLE patients avoid or even terminate 
pregnancy because of the potential negative effects of pregnancy on the 
course of disease 
[4, 5]
. Some investigators believe that the rate of flares 
during pregnancy is similar to the rate observed in non-pregnant SLE 
patients, whereas other investigators suggest that pregnancy may increase 
disease activity 
[6, 7]
.  A more recent prospective outcome study of planned 
pregnancies in patients with SLE shows that, if one excludes early 
spontaneous and induced abortions, patients with SLE can have a live birth 
rate of 96% without maternal or neonatal death, although with a high rate of 
premature births, with a 27% incidence of modest to moderate lupus flares 
[8]
.  The two most important factors associated with worse fetal outcome in 
SLE are lupus activity during the pregnancy and the presence of 
antiphospholipid (aPL) antibodies (anticardiolipin antibody and lupus 
anticoagulant) 
[9, 10]
. Pregnancy in patients with SLE is typically safe, if the 
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disease has been inactive on 20 mg or less of prednisone for at least one 
year. Our patient had been asymptomatic with normal renal function off 
steroids for over one year therefore when she inquired about becoming 
pregnant again she was advised that a potential pregnancy would not expose 
her to excessive risks.  
  
Gestational versus SLE associated thrombocytopenia 
The overall incidence of thrombocytopenia, defined as a platelet count less 
than 150,000 mm
3
,   in pregnancy varies between 5.1% and 8% 
[11]
. The 
most common cause is gestational thrombocytopenia which typically 
accounts for more than 75% of cases 
[12]
. However, thrombocytopenia is also 
common in SLE patients and has been reported to be present in 14% of 
pregnant SLE patients 
[13]
. Clearly, several aspects of the thrombocytopenia 
present in the patient reported here, such as its preexistence before the 
pregnancy, the severe degree of the thrombocytopenia, and the response to 
the steroid treatment in 2006, suggested an SLE-associated 
thrombocytopenia instead of gestational thrombocytopenia. Of note, the 
patient’s platelet count during the first trimester remained moderately low 
but within the range of values observed before her pregnancy. This is 
consistent with the available evidence suggesting that pregnancy does not 
worsen the course of immune mediated thrombocytopenia 
[14]
. However, at 
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the time of the second trimester, her platelet count had decrease to 
9,000/mm
3
; at this time she had one episode of bleeding (epistaxis) requiring 
treatment with IVIG. She had a moderate response to the IVIG with a rise of 
the platelets count to 52,000/mm
3
 on discharge from our department, and a 
decrease to the 20,000s range thereafter. 
Should she have been considered to have refractory SLE- associated 
thrombocytopenia at this time based on the decrease in platelet count while 
still on medical management? Based on the relatively short lived response to 
the treatment with IVIG with an almost immediate return of her platelet 
count to values below 25,000/mm
3
, she was unlikely to have a positive 
response to another course of IVIG, as in fact occurred when she was 
admitted for the elective C-section on the 34
th
 week of gestation.  Since she 
was in the second trimester of pregnancy should she have had a laparoscopic 
splenectomy at this time to avoid the possible bleeding hazards to her and 
her fetus associated with platelet concentrations below a critical level? There 
has been at least one case report suggesting that laparoscopic splenectomy in 
the second trimester of pregnancy is a viable therapeutic option for the 
treatment of refractory immune-mediated  thrombocytopenia in pregnancy 
[15]
.  Furthermore, if laparoscopic splenectomy is performed in the second 
trimester, the patient is very likely to have a spontaneous delivery. 
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Our hematology consultant felt that it was safe to allow the patient to 
continue her pregnancy with a platelet count above 20,000/mm
3 
and that the 
patient should undergo delivery via C-section after the 34
th
 week of gestation 
after another course of IVIG, if needed. Due to the inadequate response to 
the repeated course of IVIG, the hematologist advised that the patient have 
an open splenectomy at the time of the C-section, after transfusion of platelet 
concentrates to raise the platelet count above 50,000/mm
3
. Obviously, three 
issues are raised by the suggestions made by our hematologist: 1
st
 the route 
of delivery; 2
nd
 the need and timing for splenectomy; 3
rd
 the overall outcome 
of splenectomy for thrombocytopenia associated with SLE and the ability to 
predict the response to the splenectomy in this patient.  
The first question about the route of delivery concerns whether a vaginal 
delivery instead of the CS could have been done after having increased the 
platelet count above 50,000/mm
3
 with transfusion of platelets, delaying the 
splenectomy to a later time after having observed whether the pregnancy 
itself had an effect on the patient’s thrombocytopenia. In the past, it has been 
common practice to perform cesarean section on mothers with SLE- 
associated thrombocytopenia to decrease the potential risk on intracranial 
hemorrhage caused by a vaginal delivery 
[16, 17]
. It has also been suggested 
that fetal platelet count less than 50,000/mm
3
 may place the fetus at greater 
risk of intracranial hemorrhage therefore CS should be considered in these 
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instances 
[10]
.  Based on the potential relationship between fetal platelets 
count and the risk of intracranial bleeding, some authors have suggested the 
use of either fetal scalp blood sampling or percutaneous umbilical vein 
sampling to determine the fetal platelet count and to select the mode of 
delivery 
[18, 19]
.  However, more recent data doe not support a correlation 
between fetal scalp platelet counts and neonatal platelet count at birth and it 
provide evidence that percutaneous umbilical vein sampling is associated 
with a high incidence of complications 
[20]
. Furthermore, the universal 
application of CS delivery to pregnant patients with immune-mediated 
thrombocytopenia has not been shown to decrease the incidence of intra-
ventricular hemorrhage 
[21]
. A review of 601 infants born to women with 
immune thrombocytopenia showed that severe neonatal thrombocytopenia 
was present in 72/601 (12%) and that the neonatal intracranial hemorrhage is 
extremely rare and unrelated to the mode of delivery 
[21]
. 
The second issue is whether splenectomy was indicated at the time of the CS 
at the 34
th
 week of gestation or whether the patient should have had the 
splenectomy in the second trimester. The role and timing of splenectomy in 
pregnant SLE-patients with thrombocytopenia refractory to medical 
treatment, including IVIG, remains controversial because of the very limited 
literature available to support an evidence-based approach to these patients. 
One report, which includes five patients with immuno thrombocytopenic 
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purpura (ITP) treated with splenectomy at the time of CS in the third 
trimester of gestation, proposes that splenectomy following CS is a very 
good option for mothers with severe resistant ITP 
[22]
. This approach is also 
supported by another case report suggesting that splenectomy combined with 
CS at the 34
th
 week of gestation can provide remission of ITP 
[23]
. However, 
another case report supports laparoscopic splenectomy during the 2
nd
 
trimester has a therapeutic option since this approach may afford the patient 
the possibility of vaginal delivery in the 3
rd
 trimester 
[24].
 Obviously, it is not 
possible to identify the ‘best” evidence-based approach to these patients 
based on occasional case reports. However, since laparoscopic splenectomy 
is safe in the 2
nd
 trimester, it seems reasonable to adopt this approach that 
may prevent the need for a CS at the term of pregnancy.   
The third issue regards whether there is evidence to support the efficacy of 
splenectomy to treat thrombocytopenia associated with SLE and whether 
there are useful predictors to identify responders versus non-responders to 
splenectomy in patients with SLE-associated thrombocytopenia in pregnant 
and non-pregnant patients. Hall and his associates in 1985 reviewed the 
efficacy of splenectomy to treat thrombocytopenia associated with SLE; they 
concluded that splenectomy is not effective at curing the thrombocytopenia 
observed in patients with SLE; therefore, they suggested that it should be 
used only as a very last resort after having exhausted all other therapeutic 
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modalities 
[25]
. However, a more recent review of this issue from the Mayo 
clinic shows that splenectomy is effective in treating SLE-associated 
thrombocytopenia by providing an 88% early partial or complete response 
and a 64% sustained response rate 
[26]
.   The pathogenesis of 
thrombocytopenia in SLE is believed to result from either increased platelet 
clearance mediated by anti-platelet autoantibodies (anti-GPIIb/IIIa 
antibodies), a mechanism similar to that observed in idiopathic 
thrombocytopenic purpura (ITP) or by autoantibodies to thrombopoietin 
receptor (TPOR), which inhibits thrombopoietin-dependet 
magakaryogenesis.  The presence of anti-TPOR antibodies has been 
associated with the lack of response to IVIG and may be predictive of a poor 
response to splenectomy in patient with SLE-associated thrombocytopenia 
[27]
.    
 
Conclusions 
In conclusion, based on a thorough review of the available literature, we 
conclude that patients with SLE-associated thrombocytopenia refractory to 
medical treatment during pregnancy should undergo testing for the presence 
of anti-GPIIb/IIIa and anti-TPOR antibodies early during their pregnancy. If 
patients have anti-GPIIb/IIIa and absent anti-TORP antibodies and they fail 
to respond to IVIG, they should undergo laparoscopic splenectomy in the 
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second trimester of gestation followed by vaginal delivery at completion of 
gestation. Open splenectomy immediately following CS in the third 
trimester remains an available, safe choice, if splenectomy has not been done 
in the second trimester.   
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Obesity and infection 
 
The world is currently experiencing an obesity epidemic as declared by the 
World Health Organization. 
The traditional view is that behaviour leading to overeating and under-
activity is the major contributing factor for this worldwide epidemic. 
However, several microbes are linked to obesity in animals and humans. On 
the one hand, various microbes, including animal and human viruses, 
bacteria, parasites and scrapie agents, increase adiposity in several animal 
models. Some of these microbes show an association with human obesity, 
but conclusive evidence for a causative role of microbes in human obesity is 
lacking. On the other hand, obese individuals show an altered response to 
infections. Obesity is often associated with impaired immune function, 
which may lead to increased susceptibility to infection with a number of 
different pathogens. Hence, certain microbes appear to induce obesity, 
whereas, obesity itself may exacerbate certain other infections. Linking the 
two phenomenon is the immunological property of adipocytes and their 
progenitors.  
For instance, proliferating pre-adipocytes share embryonic origin with 
immune cells and exhibit phagocytic activity. Taken together it appears that 
there is a close interrelationship between adipose tissue, inflammatory 
response, immune system and infections. Hence, it is conceivable that in 
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response to certain infections, adipose tissue expands similar to the 
expansion of cells of the immune system. The impaired immune function of 
adipose tissue in obesity may exacerbate infections. Considering the global 
obesity epidemic, it is necessary to further investigate both phenomena. 
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